The $100 Billion GLP-1 Question: Can We Predict Patient Response?

The promise of precision medicine is simple to state and difficult to deliver: the right treatment, for the right patient, at the right time. One of the challenges is that researchers often lack access to biological data that can be linked to what happens to patients over time.  Barry Wark, Co-Founder and Chief Strategy Officer of Ovation, has spent much of his career working on one of the rate-limiting factors behind that promise: access to consented biospecimens that can be linked to longitudinal clinical outcomes. In this episode of Biology Matters, Rowan Gardner speaks with Barry about how Ovation’s approach to multi-omic human biobanking is designed to meet patients where they already are in healthcare. Instead of relying only on large, all-comers biobanks or slow prospective trials, Ovation works with real-world clinical networks to connect consented samples with health records, allowing researchers to build focused disease cohorts more quickly and study how patients actually progress and respond in routine care. **What You'll Learn:** - Why longitudinal clinical records can make biobanks more powerful for precision medicine - How “meeting patients where they are” can reduce friction in real-world data generation - Why GLP-1 response is a major test case for precision medicine in chronic disease - Why weight loss and blood sugar control may involve different biological mechanisms - How multi-omic data can support better patient stratification and clinical trial design - Why precision medicine should improve access to effective therapies, not restrict it - Why data sovereignty and insight portability can coexist in global precision medicine - How clinical data could create a feedback loop between research, treatment and patient outcomes **About Rowan** Rowan Gardner is Chief Business and Investment Officer and Co-Founder of PrecisionLife, bringing 30+ years of experience across health tech, digital health, deep tech and biotech. Her expertise spans venture funding, strategic partnerships and translating breakthrough science into real-world healthcare impact across multiple continents. At PrecisionLife, Rowan focuses on how better biological understanding, patient stratification and mechanism-based insights can help healthcare move from broad diagnostic labels toward earlier diagnosis, more precise treatment selection and more effective chronic disease management. **About Barry** Barry Wark is Co-Founder and Chief Strategy Officer of Ovation, a multi-omic human biobank company focused on accelerating precision medicine through consented biospecimens linked to longitudinal clinical outcomes. He holds a degree in Symbolic Systems from Stanford University and a PhD in Neurobiology and Behavior from the University of Washington. Barry’s work sits at the intersection of life science data, translational research and precision medicine infrastructure. His early experience in research data management showed him how much scientific value can remain locked inside disconnected datasets. That insight ultimately shaped Ovation’s mission: to make high-quality, real-world patient data available when researchers, healthcare systems and life science organizations need it. **Episode Resources:**  Barry Wark on LinkedIn  Ovation Website Rowan Gardner on LinkedIn PrecisionLife Website Biology Matters is handcrafted by our friends over at: fame.so